Par Pharma snags new COO from Glenmark; GSK says patients prefer Votrient; Sanofi wins expanded use for tDAP shot;

@FiercePharma: Industry predicts dire consequences from FDA's generic labeling proposal. News | Follow @FiercePharma

@TracyStaton: GSK ditches ovarian cancer plans for Votrient after failed study. More | Follow @TracyStaton

@EricPFierce: GSK attacks African market with combo of goodwill, R&D and plant projects. Article | Follow @EricPFierce

@CarlyHFierce: Biogen's Alprolix nod is just the first tremor in a hemophilia market shake-up- FiercePharmaMarketing. Story | Follow @CarlyHFierce

> Par Pharmaceutical, based in Woodcliff Lake, NJ, brought on Terrance Coughlin as chief operating officer; previously, he was president and CEO of Glenmark Generics' U.S. group. Release

> GlaxoSmithKline ($GSK) touted a new study showing that its kidney cancer drug Votrient was preferred by patients, compared with Pfizer's ($PFE) competing treatment, Sutent. Report

> Sanofi ($SNY) said its vaccines division won expanded FDA approval for its Adacel combination vaccine, in children 10 years of age. Release

> AstraZeneca ($AZN) is rolling out cloud-based human resources software to 66,000 staff around the globe. Report

> Germany-based Merck Serono is mounting an effort to increase biomarker testing in patients with metastatic colorectal cancer. Report

> Johnson & Johnson ($JNJ) has signed on as the official healthcare partner of the USO. Report

Medical Device News

@FierceMedDev: Four months later 23andMe's clash with the FDA over regulation of OTC genetic tests remains unresolved. Story | Follow @FierceMedDev

@MarkHFierce: Check out the latest FierceDiagnostics, with news involving Pfizer, colon cancer tests and HIV Dx funding. Report | Follow @MarkHFierce

@MichaelGFierce: In drug delivery, it's the little things that count. Looking back on the year in nanotech drug delivery. Special report | Follow @MichaelGFierce

@EmilyWFierce: Researchers at Cornell delve into "cereal box psychology" with new study on supermarkets and spokes-characters. Article | Follow @EmilyWFierce

> Thoratec smacked with FDA Class I recall concerning heart pump backup controllers. More

> Boston Scientific touts promising trial data for its transcatheter valve. Story

> Cepheid's 60-minute HPV test is now available in Europe. Item

Biotech News

@FierceBiotech: Stallergenes beats Merck to market as the FDA OKs its allergy pill. More | Follow @FierceBiotech

@JohnCFierce: Analysts, experts are dazzled by the blockbuster potential of Novartis' LCZ696. News | Follow @JohnCFierce

@DamianFierce: MannKind jumps ~125% after positive panel vote, reaching a four-year high. Story | Follow @DamianFierce

@EmilyMFierce: Most popular at FierceBiotechResearch.com: Committee finds 'scientific misconduct' in blockbuster stem cell papers. Article | Follow @EmilyMFierce

> GlaxoSmithKline shutters lung cancer vaccine study on latest MAGE-A3 setback. News

> Baxter snaps up its hemophilia partner on the verge of a biotech breakup. Story

Drug Delivery News

> Enzyme micropumps deliver insulin in response to glucose levels. Story

> Hydrogel delivers inhibitors directly to reduce damage after a heart attack. Article

> Harvard researchers create method to measure nano exposure for safety, delivery. News

> Water excited by infrared light melts nanoparticles to release drugs. Article

> DNA nanorobot delivers drugs through flap that opens and closes. Story

> Wearable data-storing 'electronic skin' could deliver drugs for epilepsy, Parkinson's. Brief

Diagnostics News

> Pfizer leads $21M Series B for a Michigan molecular Dx startup. News

> Exact Sciences' and Epigenomics' colon cancer tests clear FDA panel with mixed results. News

> New septic shock biomarker Dx could produce better care and smoother drug trials. Article

> U.K. team scores with blood test that might spot children likely to become obese. Story

> Zyomyx snags $7.5M from WHO's UNITAID to fund HIV/AIDS test in emerging markets. News

> Finding: 2 biomarkers for head and neck cancer can help predict radiation therapy resistance. Brief

Pharma Marketing News

> Sanofi aims for outcomes with brand-new Chief Patient Officer. Story

> Eli Lilly's sales force finds CRM harmony in the cloud. Article

> Biogen's Alprolix nod is just the first tremor in a hemophilia market shake-up. Story

> Can statin-maker Kowa help Amarin jump-start Vascepa sales? Article

> Auxilium aims Stendra's sexy March Madness ads at stiff ED competition. Story

> ViiV opens up brand-new HIV med Tivicay for cheap copies in poor countries. Brief

And Finally... Two big studies found links between low vitamin D levels and deadly disease, but couldn't determine whether low levels cause disease or indicate disease-causing behaviors such as an unhealthy diet. Report

Suggested Articles

Novartis is rolling out head-to-head data for its MS drug in advance of an expected FDA approval next month, but competition will still be tough.

The FDA knocked Altaire Pharmaceuticals for falsified data and harebrained contraptions at its New York plant in a scathing warning letter.

BMS' Opdivo and Yervoy only just won their first approval in previously untreated metastatic NSCLC, but the pair is already making it two.